ANTIULCER ACTIVITY OF DINITRATE 2-PHENYL-9DIETHYLAMINOETHYLAMINE[1,2-A]BENZIMIDAZOLE WITH HELICOBACTER PYLORI-LIKE DAMAGE OF GASTRIC MUCOSA

The search for new drugs providing effective and safe therapy of acid-dependent diseases of the gastrointestinal tract, continues to be an actual problem of modern pharmacotherapy. One of the most significant pathogenetic mechanisms of these diseases is associated with Helicobacter pylori damage to the gastric mucosa.

The aim of this study is the experimental investigation of the antiulcer effect of 2-phenyl-9-diethylaminoethylamine [1,2-a] benzimidazole substance (hereinafter a Benzimidazole derivative substance) on the model of Helicobacter pylori-like gastric mucosal injury in combination with immobilization stress (a restraint).

Materials and methods. For modeling a mucous membrane damage to experimental animals (white Wistar male rats), they were injected 120 mmol/l ammonia solution after a 24-hour immobilization stress (restraint). As reference drugs, the following officinal anti-ulcer drugs widely used in clinical practice, had been chosen: Rranitidine (30 mg/kg, 10 mg/kg and 3 mg/kg) and Omeprazole (3 mg/kg, 1 mg/kg and 0.3 mg/kg). The study substance was used in the doses of 30 mg/kg, 10 mg/kg and 3 mg/kg. The maximum doses of the reference drugs were calculated on the basis of maximum daily doses for humans, taking into consideration the interspecies conversion factor. The maximum dose of the substance under study was selected experimentally. The logarithmic dose range was used for the convenience of further calculations of the ED₅₀ value. All the studied objects were introduced intragastrically through a non-traumatic tube.

Results and discussion. It has been established that the studied substance significantly reduced the area of mucosal damage relative to the control values in modeling Helicobacter pylori-like gastric mucosal injury provoked by the administration of ammonia solution against the background of gastric mucosal ischemia after a 24-hour restraint. At the same time, the inhibition of ulceration reached 78%, while in the groups receiving Ranitidine and Omeprazole, it reached 66% and 50%, respectively. The calculated ED₅₀ values were the following: for the substance under study – 16.03 mg/kg, and for Ranitidine – 15.99 mg/kg.

Conclusion. The gained results indicate that the studied Benzimidazole derivative is superior to analogs in its ability to suppress gastric mucosal ulceration provoked by Helicobacter pylori-like gastric mucosal injury, which confirms the relevance of further study of anti-ulcer activity and the development of the pharmaceutical dosage form based on it.

1. Krishna Prasad PM, Avdhut K. Potent biological agent benzimidazole–a review. Int. J. of Pharmacy and Pharm. Sciences. 2016;8(12):22–33.

2. Shah K, Chhabra S, Shrivastava SK, Mishra P. Benzimidazole: A promising pharmacophore. Med. Chem. Research. 2013;22(11):5077–104.

3. Abu-Bakr SM, Bassyouni FA, Rehim MA. Pharmacological evaluation of benzimidazole derivatives with potential antiviral and antitumor activity. Research on Chemical Intermediates. 2012;38(9):2523–45.

4. Lutz P. Benzimidazole and its derivatives – from fungicides to designer drugs. A new occupational and environmental hazards. Medycyna pracy. 2012;63(4):505–13.

5. Keri RS, Rajappa CK, Patil SA, Nagaraja BM. Benzimidazole-core as an antimycobacterial agent. Pharmacological Reports. 2016;68(6):1254–65.

6. Singh N, Pandurangan A, Ranaet K. Benzimidazole: A short review of their antimicrobial activities. Int. Current Pharm. J. 2012;1(5):119–27.

7. Yadav S, Narasimhan B, Kaur H. Perspectives of Benzimidazole derivatives as anticancer agents in the new era. Anti-Cancer Agents in Med. Chem. 2016;16(11):1403–25.

8. Shrivastava N, Naim MJ, Alam MdJ. Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure–Activity Relationship. Archiv der Pharmazie. 2017;350(6):1–80. DOI: 10.1002/ardp.201700040

9. Furtado LFV, de Paiva Bello ACP, Rabelo ÉML. Benzimidazole resistance in helminths: From problem to diagnosis. Acta Tropica. 2016;162:95–102.

10. Achar KCS, Hosamani KM. In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. Eur. J. Med. Chem. 2010;45:2048–54.

11. Gaba M, Singh S, Mohan C. Benzimidazole: an emerging scaffold for analgesic and anti- inflammatory agents. Eur. J. Med. Chem. 2014;76:494–505.

12. Kim RM, Chang J, Lins AR. Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 2008;18:3701.

13. Perez-Villanueva J, Hernandez-Campos A, Yepez-Mulia L. Synthesis and antiprotozoal activity of novel 2-{[2-(1H-imidazol-1-yl)ethyl]sulfanyl}-1H-benzimidazole derivatives. Bioorg. Med. Chem. Lett. 2013;23(14):4221–4.

14. Ates-Alagoz Z. Antioxidant activities of retinoidal benzimidazole or indole derivatives in In vitro model systems. Current Med. Chem. 2013;20(36):4633–9.

15. Vasil’ev PM, Kalitin KYu, Spasov AA. Prediction and study of anticonvulsant properties of benzimidazole derivatives. Pharm. Chem. J. 2017;50(12):775–80.

16. Jain ZJ, Kankate RS, Chaudhari BN, Kakad RD. Action of benzimidazolo-piperazinyl derivatives on dopamine receptors. Med. Chem. Research. 2013;22(2):520–30.

17. Patil A, Ganguly S, Surana S. A systematic review of benzimidazole derivatives as an antiulcer agent. Rasayan J. Chem. 2008;1(3):447–60.

18. Sharma K, Dudhe A. A review on various heterocyclic moieties and their antitubercular activity. Biomedicine and Pharmacotherapy. 2011;65(4):244–51.

19. Galenko-Yaroshevsky PA, Galenko-Yaroshevsky AP, Anisimov VA, Chemodanova PS. Proizvodnye benzimidazola: mestnoanesteziruyushchie svojstva, mekhanizmy dejstviya, perspektivy ispol’zovaniya v oftal’mologii [Derivatives of benzimidazole: local anesthetic properties, mechanisms of action, prospects for use in ophthalmology]. Monograph. Krasnodar: Prosveshenie;2015. 781 p. Russian.

20. Microb Pathog. 2018 Jun 21. pii: S0882-4010(17)31766-7.

21. Patofiziologiya [Pathophysiology]: textbook: in 2 Vol. Novitskogo VV, Goldberg ED, Urazova OI, editors. 4th ed. I DOP. GEOTAR-Media, 2009;1:848. Russian.

22. Mayev IV, Samsonov AA, Golubev NN. Helikobakter-associirovannaya forma yazvennoj bolezni zheludka i dvenadcatiperstnoj kishki: problemy terapii [Helicobacter-associated form of gastric ulcer and duodenal ulcer: problems of therapy]. Pharmateca. 2011;2:10-7. Russian.

23. Spasov AA. Pat. Lekarstvennaya substanciya dlya podavleniya gelikobakteropodobnyh erozivno-yazvennyh povrezhdenij slizistoj obolochki zheludka The drug substance for suppressing gelikobakterioza erosive-ulcerative lesions of the gastric mucosa. RU 2395282; No. 2008136173/15; Appl. 09.09.2008; publ. 10.04.10. Available from: http://www1.fips.ru/fips_servl/fips_servlet Russian.

24. Spasov AA, Chernikov MV, Speranskaya AS, Zaichenko SI. Effects of Misoprostol and Taurine on Monochloramine Ulcerogenesis in Rats. Bulletin of Experimental Biology and Medicine. 2006;141(3).

25. Principy nadlezhashchej laboratornoj praktiki [Russian government technical requirements R 33044-2014]. The principles of good laboratory practice. (OECD Guide 1:1998, IDT). Moscow: STANDARTINFORM, 2015. 11 p. Russian.

26. Prikaz Ministerstva zdravoohraneniya RF ot 1 aprelya 2016 g. N 199n “Ob utverzhdenii «Pravil nadlezhashchej laboratornoj praktiki” [Order of the Ministry of health of the Russian Federation of April 1, 2016 N 199n “About the approval Of rules of good laboratory practice”] (Registered in the Ministry of justice of the Russian Federation on August 15, 2016 N 43232). Bulletin of regulations of Federal Executive authorities. N 37. 12.09.16 Russian.

27. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv [Guidelines for preclinical studies of drugs]. Part I. Mironov AN, Bunatyan ND, Vasil’ev AN, editors. Mockva: Vulture and K, 2012. 944 p. Russian.

28. Adinortey MB, Ansah C, Galyuon I, Nyarko A. In vivo models used for evaluation of potential antigastroduodenal ulcer. Ulcers. 2013;2013:1 -12. DOI: 10.1155/2013/796405